Journalism of Courage
Premium

WHO alert on another ‘contaminated’ cough syrup made in India, third in 7 months

The alert says Guaifenesin was found to contain ‘unacceptable amounts of diethylene glycol and ethylene glycol’ by the quality control labs of the Therapeutic Goods Administration of Australia.

cough syrup deathsNoida-based Marion Biotech came under the scanner following the death of 18 children in Uzbekistan allegedly after consuming its cough syrup. (Representational image)
Advertisement
Listen to this article Your browser does not support the audio element.

The World Health Organisation has issued another alert for an India-manufactured, contaminated cough syrup sold in the Marshall Islands and Micronesia. This is the third such alert within seven months for contaminated cough syrups produced in India, with the previous cases having been identified in the Gambia and Uzbekistan.

The alert says that the syrup Guaifenesin—used to relieve chest congestion and cough—was found to contain “unacceptable amounts of diethylene glycol and ethylene glycol” by the quality control labs of the Therapeutic Goods Administration of Australia. These are the same contaminants that were found in syrups allegedly linked to the deaths of 70 children in the Gambia and 18 children in Uzbekistan due to acute kidney injury.

The alert asks people to not use the syrup and regulators to increase surveillance of supply chains. It also asks manufacturers to test raw materials used in such syrups such as propylene glycol, sorbitol and glycerine/glycerol before using them in a medical formulation.

The most likely source of the two contaminants is thought to be contaminated solvents that are used for the manufacturing of the syrups. While the solvents used are not harmful, both the contaminants are known to be toxic to humans. They can lead to abdominal pain, vomiting, diarrhoea, headache, altered mental status, inability to pass urine and acute kidney injury. The contaminants can also be fatal.

The contaminants were reported from one batch of the medicine with an expiry date in October 2023. The contamination was reported to the WHO on April 6, according to the alert issued on Tuesday night.

The syrup sold in the two Pacific Ocean countries was stated to have been manufactured by Punjab-based QP Pharmachem Ltd and marketed by Haryana-based Trillium Pharma. “To date, neither the stated manufacturer nor the marketer have provided guarantees to WHO on the safety and quality of these products,” the WHO said.

In the previous two cases, teams of central and state drug inspectors were rushed to the manufacturing facilities and manufacturing was halted for violations of good manufacturing practices. While contamination was not detected in the control samples or raw materials collected from Maiden Pharma, linked to the cases in the Gambia, it was detected in raw material collected from Marion Biotech, linked to the Uzbek cases. A case was registered against the company.

Story continues below this ad

In another incident, an India-manufactured eye drop was linked to an outbreak of highly resistant bacterial infections in the United States.

The government has since started conducting risk-based inspections of drug manufacturers in India and cancelled the licences of 18 companies and permissions for particular products at three companies. The cases have come at a time when India is trying to highlight its image as the pharmacy of the world providing affordable, quality medicines.

Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government’s management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country’s space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University’s Dart Centre. Dutt has a Bachelor’s Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More

Stay updated with the latest - Click here to follow us on Instagram

Tags:
  • WHO
Edition
Install the Express App for
a better experience
Featured
Trending Topics
News
Multimedia
Follow Us
C Raja Mohan writesIn a multi-polar West, India’s opportunity
X